There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report), Arcutis Biotherapeutics (ARQT – Research Report) and TruBridge (TBRG – Research Report) with bullish sentiments.
Acrivon Therapeutics, Inc. (ACRV)
In a report released yesterday, Marc Frahm from TD Cowen maintained a Buy rating on Acrivon Therapeutics, Inc.. The company’s shares closed last Tuesday at $8.36.
According to TipRanks.com, Frahm is a 5-star analyst with an average return of
Currently, the analyst consensus on Acrivon Therapeutics, Inc. is a Strong Buy with an average price target of $23.00, which is a 176.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Arcutis Biotherapeutics (ARQT)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $8.13.
According to TipRanks.com, Buren is a 3-star analyst with an average return of
Currently, the analyst consensus on Arcutis Biotherapeutics is a Moderate Buy with an average price target of $16.40, representing a 101.5% upside. In a report issued on May 3, Mizuho Securities also maintained a Buy rating on the stock with a $17.00 price target.
TruBridge (TBRG)
RBC Capital analyst Sean Dodge maintained a Buy rating on TruBridge on May 10 and set a price target of $13.00. The company’s shares closed last Tuesday at $8.80, close to its 52-week low of $7.55.
According to TipRanks.com, Dodge has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on TruBridge is a Moderate Buy with an average price target of $11.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACRV:
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
- Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
- Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
- Acrivon Therapeutics Inc trading resumes
